Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1186 - Cabazitaxel plus prednisolone with primary prophylaxis with pegfilgrastim (PEG) in Japanese patients with metastatic castration-resistant prostate cancer: An open label prospective phase 2 study (519P)

Date

18 Nov 2017

Session

Poster lunch

Presenters

Hiroji Uemura

Citation

Annals of Oncology (2017) 28 (suppl_10): x155-x165. 10.1093/annonc/mdx676

Authors

H. Uemura1, T. Kosaka2, M. Sumitomo3, K. Harada4, M. Sugimoto5, N. Hayashi6, K. Yoshimura7, S. Fukasawa8, E.B. Ecstein-Fraisse9, Y. Sunaga10, M. Oya2

Author affiliations

  • 1 Department Of Urology/renal Transplantation, Yokohama City University Medical Center, 232-0024 - Yokohama/JP
  • 2 Department Of Urology, Keio University Hospital, Tokyo/JP
  • 3 Department Of Urology, Aichi Medical University Hospital, Aichi/JP
  • 4 Department Of Urology, Kobe University Hospital, Kobe/JP
  • 5 Department Of Urology, Kagawa University Hospital, Kagawa/JP
  • 6 Department Of Urology, Yokohama City University Hospital, Yokohama/JP
  • 7 Department Of Urology, Kindai University Hospital, Osaka/JP
  • 8 Department Of Urology/prostate Cancer, Chiba Cancer Center, Chiba/JP
  • 9 Medical, Sanofi France, Paris/FR
  • 10 Biostatistics & Programming, Sanofi Japan, Tokyo/JP
More

Resources

Abstract 1186

Background

Pegfilgrastim (PEG) is used for chemotherapy-induced febrile neutropenia (FN) prophylaxis. FN was observed in 54.5% of patients (pts) who received cabazitaxel (CBZ) 25 mg/m2 in a Japanese phase I study (NCT01324583). This phase 2 study assessed the efficacy and safety of prophylactic use of PEG in Japanese pts with metastatic castration-resistant prostate cancer (mCRPC) treated with CBZ plus prednisolone (P).

Methods

Pts previously treated with docetaxel received CBZ 25 mg/m2 Q3W + P 10 mg daily (maximum 10 cycles). PEG was administered on day 2 in the first and subsequent cycles. The primary endpoint was incidence of FN (absolute neutrophil count [ANC]  38.3 °C or sustained temperature of ≥ 38 °C for >1 h) in cycle 1. Decrease (≥50%) in PSA, time-to-PSA progression, and other safety parameters were assessed.

Results

Twenty-one pts (median age 70 years, ECOG-PS 0 or 1 [100%]) were enrolled; 61.9% had prior enzalutamide and 47.6% had prior abiraterone. The median number of cycles of treatment was 7.0; 9 (42.9%) pts completed 10 cycles; 9 (42.9%) discontinued because of disease progression and 3 (14.3%) discontinued because of adverse events. The median relative dose intensity for CBZ was 67.4%. Two (9.5%) pts presented with FN (95% confidence interval [CI], 1.17–30.38) in cycle 1 only. The median ANC nadir was 68.0/mm3 (range, 0–1740/mm3), median days to nadir was 8.0 (range, 7–9) and days to recovery was 4.0 (range, 3–9). Grade 3/4 treatment-emergent adverse events were observed in 21 (100%) pts (Table). There were no toxicity-related deaths. PSA response was observed in 6 (28.6%) pts (95% CI, 11.28–52.18) and the median time to PSA progression was 182 days (95% CI, 71–255).Table: 519P

Grade 3/4 treatment-emergent adverse events. Number of patients = 21.

Grade 3/4 TEAE (≥ 5%)n (%)
Neutropenia20 (95.2)
Thrombocytopenia5 (23.8)
Leukopenia3 (14.3)
Febrile neutropenia2 (9.5)
Decreased appetite2 (9.5)

Conclusions

CBZ plus P with prophylactic use of PEG was well tolerated in Japanese mCRPC pts.

Clinical trial identification

NCT 02441894.

Legal entity responsible for the study

Sanofi K. K.

Funding

Sanofi K. K.

Disclosure

H. Uemura: Consultancy fees from Janssen, Astellas, Takeda, Bayer, Daiichi Sankyo; lecture fees from AstraZeneca, Sanofi, Fujifilm, Kyowa Hakko Kirin, Kissei. M. Sumitomo: Consultancy fees from Sanofi, Janssen, Ono, Pfizer, Takeda, Kissei; lecture fees from Sanofi, Pfizer, Takeda, AstraZeneca; research funding from Ono, Sanofi, Astellas, AstraZeneca, Takeda. M. Sugimoto: Manuscript writing/editing fees from Janssen, Astellas, Takeda, AstraZeneca. E.B. Ecstein-Fraisse: Employee of Sanofi. Y. Sunaga: Stock ownership and employee of Sanofi. M. Oya: Consultancy fees from Astellas.; lecture fees from Astellas, Janssen, AstraZeneca, Sanofi, Takeda; research funding from Astellas, Takeda.

All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.